BFW 04/08 17:03 Perrigo Board to Meet to Discuss Mylan Proposal
BN 04/08 17:00 *PERRIGO BOARD TO MEET TO DISCUSS PROPOSAL
BFW 04/08 17:00 *PERRIGO CONFIRMS IT HAS RECEIVED A PROPOSAL FROM MYLAN
BN 04/08 17:00 *PERRIGO: NO CERTAINTY ANY OFFER WILL BE MADE
BN 04/08 17:00 *PERRIGO CONFIRMS IT HAS RECEIVED A PROPOSAL FROM MYLAN
BN 04/08 17:00 *PERRIGO: WILL MEET TO DISCUSS PROPOSAL
BN 04/08 17:00 *PERRIGO CONFIRMS IT HAS RECEIVED PROPOSAL FROM MYLAN
BN 04/08 17:00 *PERRIGO BOARD TO MEET TO DISCUSS PROPOSAL
BFW 04/08 17:00 *PERRIGO CONFIRMS IT HAS RECEIVED A PROPOSAL FROM MYLAN
BN 04/08 17:00 *PERRIGO: NO CERTAINTY ANY OFFER WILL BE MADE
BN 04/08 17:00 *PERRIGO CONFIRMS IT HAS RECEIVED A PROPOSAL FROM MYLAN
BN 04/08 17:00 *PERRIGO: WILL MEET TO DISCUSS PROPOSAL
BN 04/08 17:00 *PERRIGO CONFIRMS IT HAS RECEIVED PROPOSAL FROM MYLAN
Announcement Regarding Possible Offer
2015-04-08 17:00:17.908 GMT
Announcement Regarding Possible Offer
This is an announcement falling under Rule 2.4 of Irish Takeover Panel Act,
1997, Takeover Rules, 2013 (the "Takeover Rules").
PR Newswire
DUBLIN, April 8, 2015
DUBLIN, April 8, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the
"Company") (NYSE: PRGO; TASE) notes the announcement made by Mylan NV
("Mylan") (NASDAQ: MYL). Perrigo confirms that it has received an
unsolicited, indicative proposal from Mylan regarding a possible offer for the
Company (the "Proposal").
Perrigo Company.
The Board of Perrigo will meet to discuss the Proposal and a further
announcement will be made when appropriate.
There can be no certainty that any offer will be made.
About Perrigo
Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods
and pharmaceutical company, offers consumers and customers high quality
products at affordable prices. From its beginnings in 1887 as a packager of
generic home remedies, Perrigo, headquartered in Ireland, has grown to become
the world's largest manufacturer of OTC products and supplier of infant
formulas for the store brand market. The Company is also a leading provider of
generic extended topical prescription products and receives royalties from
Multiple Sclerosis drug Tysabri®. Perrigo provides "Quality Affordable
Healthcare Products®" across a wide variety of product categories and
geographies primarily in North America, Europe, and Australia, as well as
other key markets including Israel and China.
A copy of this announcement will be available on Perrigo's website at
www.perrigo.com.
The Directors of Perrigo accept responsibility for the information contained
in this announcement. To the best of their knowledge and belief (having taken
all reasonable care to ensure such is the case), the information contained in
this announcement is in accordance with the facts and does not omit anything
likely to affect the import of such information.
A person interested in 1% or more of any class of relevant securities of
Perrigo may have disclosure obligations under Rule 8.3 of the Irish Takeover
Rules, effective from the date of this announcement.
A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed can be found on the Irish Takeover
Panel's website at www.irishtakeoverpanel.ie. "Interests in securities" arise,
in summary, when a person has long economic exposure, whether conditional or
absolute, to changes in the price of securities. In particular, a person will
be treated as having an "interest" by virtue of the ownership or control of
securities, or by virtue of any option in respect of, or derivative referenced
to, securities. Terms in quotation marks are defined in the Irish Takeover
Rules, which can be found on the Irish Takeover Panel's website.
If you are in any doubt as to whether or not you are required to disclose a
"dealing" under Rule 8, please consult the Irish Takeover Panel's website at
www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone
number +353 1 678 9020; fax number +353 1 678 9289.
Logo - http://photos.prnewswire.com/prnh/20120301/DE62255LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/announcement-regarding-possible-offer-300062930.html
SOURCE Perrigo Company plc
Website: http://www.perrigo.com
Contact: Arthur J. Shannon, Vice President, Investor Relations and Global
Communications, (269) 686-1709, ajshannon@perrigo.com, or Bradley Joseph,
Director, Investor Relations and Global Communications, (269) 686-3373,
bradley.joseph@perrigo.com
-0- Apr/08/2015 17:00 GMT
2015-04-08 17:00:17.908 GMT
Announcement Regarding Possible Offer
This is an announcement falling under Rule 2.4 of Irish Takeover Panel Act,
1997, Takeover Rules, 2013 (the "Takeover Rules").
PR Newswire
DUBLIN, April 8, 2015
DUBLIN, April 8, 2015 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the
"Company") (NYSE: PRGO; TASE) notes the announcement made by Mylan NV
("Mylan") (NASDAQ: MYL). Perrigo confirms that it has received an
unsolicited, indicative proposal from Mylan regarding a possible offer for the
Company (the "Proposal").
Perrigo Company.
The Board of Perrigo will meet to discuss the Proposal and a further
announcement will be made when appropriate.
There can be no certainty that any offer will be made.
About Perrigo
Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods
and pharmaceutical company, offers consumers and customers high quality
products at affordable prices. From its beginnings in 1887 as a packager of
generic home remedies, Perrigo, headquartered in Ireland, has grown to become
the world's largest manufacturer of OTC products and supplier of infant
formulas for the store brand market. The Company is also a leading provider of
generic extended topical prescription products and receives royalties from
Multiple Sclerosis drug Tysabri®. Perrigo provides "Quality Affordable
Healthcare Products®" across a wide variety of product categories and
geographies primarily in North America, Europe, and Australia, as well as
other key markets including Israel and China.
A copy of this announcement will be available on Perrigo's website at
www.perrigo.com.
The Directors of Perrigo accept responsibility for the information contained
in this announcement. To the best of their knowledge and belief (having taken
all reasonable care to ensure such is the case), the information contained in
this announcement is in accordance with the facts and does not omit anything
likely to affect the import of such information.
A person interested in 1% or more of any class of relevant securities of
Perrigo may have disclosure obligations under Rule 8.3 of the Irish Takeover
Rules, effective from the date of this announcement.
A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed can be found on the Irish Takeover
Panel's website at www.irishtakeoverpanel.ie. "Interests in securities" arise,
in summary, when a person has long economic exposure, whether conditional or
absolute, to changes in the price of securities. In particular, a person will
be treated as having an "interest" by virtue of the ownership or control of
securities, or by virtue of any option in respect of, or derivative referenced
to, securities. Terms in quotation marks are defined in the Irish Takeover
Rules, which can be found on the Irish Takeover Panel's website.
If you are in any doubt as to whether or not you are required to disclose a
"dealing" under Rule 8, please consult the Irish Takeover Panel's website at
www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone
number +353 1 678 9020; fax number +353 1 678 9289.
Logo - http://photos.prnewswire.com/prnh/20120301/DE62255LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/announcement-regarding-possible-offer-300062930.html
SOURCE Perrigo Company plc
Website: http://www.perrigo.com
Contact: Arthur J. Shannon, Vice President, Investor Relations and Global
Communications, (269) 686-1709, ajshannon@perrigo.com, or Bradley Joseph,
Director, Investor Relations and Global Communications, (269) 686-3373,
bradley.joseph@perrigo.com
-0- Apr/08/2015 17:00 GMT